Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 9, 2021 7:30 AM EDT

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.

Second quarter CAPLYTA total prescriptions (TRx) increased 22% versus the previous quarter.

Total revenues for the second quarter were $20.0 million. CAPLYTA achieved net product revenues of $19.0 million for the second quarter.

Patient enrollment in Study 501, a Phase 3 clinical trial evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD), has commenced.

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.... More